Table 1.

Summary of patient cases with continuous infusion beta-lactam antibiotics for the treatment of P. aeruginosa infections

Case #	Age / Gender	Primary Diagnosis	Type of Infection	Beta- lactam Antibiotic	Weight (kg)	Scra (mg/dL) -------- CrCl (mL/min)	Dosage	Target Css (mg/L)	Outcome
1	18 yo Female	Primary immunodeficiency Cutaneous T cell lymphoma/leukemia	Blood stream	ceftazidime	40	0.4 144 mL/min	9/19 LD: 2 g IV 9/19 – 9/22 MD: 271 mg/h 9/22 – 9/29 MD: 400 mg/h	80 to 100	Blood culture negative on repeat cultures Deceased
2	17 yo Male	Leukocyte adhesion deficiency type 1	Wound Pneumonia	aztreonam	49	11/26 0.7 11/30 0.7 52.6 mL/minb 12/1 0.6	11/26 – 11/27 LD: not given MD: 260 mg/h 12/1 – 8/17 LD: not given MD: 350 mg/h	> 16	Wounds healed Pneumonia resolved
3	44 yo Male	Severe aplastic anemia	Pneumonia Blood stream	ceftazidime	71.4	2/19 0.8 110 mL/min 3/18 1 88 mL/min 3/21 1.3 68 mL/min 3/25 1 88 mL/min	2/19 – 2/24 3/11 – 3/14c LD: not given MD: 700 mg/h 3/18 – 3/21 LD: not given MD: 417 mg/h 3/21 – 3/25 MD: 375 mg/h 3/25 – 4/29 MD: 292 mg/h	64 to 100	Bacteremia cleared and pneumonia improved with initial treatment Patient subsequently developed bacteremia, pneumonia, and meningitis Deceased

^a= serum creatinine at start of continuous infusion beta-lactam antibiotic therapy

^b= measured CrCl from a 24 hour urine collection adjusted for body surface area

^c= new pulmonary infiltrates thought to be caused by recurrent P. aeruginosa were associated with pleuritic chest pain and prompted a change to ceftazidime 2 g IV every 8h from 3/14 to 3/18

CrCl = estimated creatinine clearance

LD = loading dose

MD = maintenance dose